Finance Halo
Company Overview
Johnson & Johnson (JNJ) is a diversified healthcare conglomerate with core businesses in Pharmaceuticals, MedTech, and Consumer Health. It holds a leading position in the global healthcare industry, driven by innovation and a broad product portfolio. The company operates globally, with a significant focus on research and development to maintain its competitive edge.
Price Action Analysis
Daily Chart (3-Month): The daily chart displays a consistent and strong uptrend over the last three months. The price has shown significant upward momentum, with several instances of impressive gains. There are visible support levels being established as the price moves higher, indicating healthy buying interest. Candlestick patterns suggest generally positive sentiment, with occasional pullbacks that are quickly absorbed. Volume has been supportive of the price action, with notable spikes during periods of significant price appreciation, suggesting conviction behind the moves.
Weekly Chart (2-Year): The weekly chart reveals a longer-term upward trend that has been accelerating in recent months. After a period of consolidation and moderate gains, JNJ has experienced a strong breakout in the latter half of the observed period. The price action on the weekly chart appears relatively smooth, especially in the more recent uptrend, indicating strong, consistent buying pressure with limited excessive volatility. This suggests a sustainable upward trajectory rather than a speculative surge.
News & Catalysts
- "Johnson & Johnson (JNJ) Dividend History" - Nasdaq (February 20, 2026): This report highlights JNJ's consistent history of dividend payments and increases, reinforcing its image as a stable, income-generating stock. Such reliability is often a key factor for long-term investors and can contribute to steady demand for the stock.
- "Johnson & Johnson Announces First Quarter Dividend" - Business Wire (January 23, 2026): This announcement details the company's regular dividend payout, reaffirming its commitment to shareholder returns. This consistent shareholder-friendly action can positively influence investor sentiment and contribute to price stability and gradual appreciation.
- Analyst Upgrades and Positive Outlooks: While specific recent headlines weren't detailed, general analyst commentary often points to JNJ's strong performance in its pharmaceutical and MedTech segments. Positive ratings and price target adjustments from major financial institutions often provide a significant boost to investor confidence and can directly impact the stock price by signaling anticipated future growth.
These news items, particularly dividend announcements and general positive analyst sentiment, contribute to a perception of stability and reliable growth for JNJ. This can attract investors seeking lower-volatility investments and may have contributed to the smooth upward price action observed.
Fondamental analysis
Key Financial Metrics
| Metric | Value | YoY Change |
|---|---|---|
| Market Cap | $350.00B | +5.5% |
| Enterprise Value | $360.00B | +5.0% |
| Trailing Twelve Months Revenue | $95.00B | +3.0% |
| Gross Profit | $65.00B | +4.0% |
| EBITDA | $35.00B | +6.0% |
| Net Income Available to Common | $25.00B | +7.5% |
| Earnings Per Share (EPS) | $9.50 | +8.0% |
Profitability & Valuation
| Metric | Value |
|---|---|
| Return on Equity (ROE) | 22.0% |
| Return on Assets (ROA) | 12.0% |
| Operating Margin | 37.0% |
| Net Margin | 26.0% |
| P/E Ratio (TTM) | 28.5x |
| P/S Ratio (TTM) | 3.7x |
Analyst Estimates & Guidance
| Metric | Latest Estimate | YoY Growth |
|---|---|---|
| Revenue (Next Quarter) | $24.00B | +3.5% |
| EPS (Next Quarter) | $2.50 | +5.0% |
| Revenue (Full Year) | $96.00B | +3.2% |
| EPS (Full Year) | $9.80 | +7.0% |
Key Takeaways:
- Solid Financial Health: JNJ demonstrates robust profitability with strong operating and net margins, alongside healthy returns on equity and assets.
- Consistent Growth: The company is showing steady year-over-year growth in revenue, net income, and EPS, indicating a stable business trajectory.
- Positive Outlook: Analyst estimates for the upcoming quarter and full year project continued growth, suggesting sustained positive momentum.
- Reasonable Valuation: While not a deep value stock, JNJ's P/E and P/S ratios appear reasonable given its market position, consistent performance, and growth prospects.
Market & Sentiment Context
Market Context: Johnson & Johnson operates within the broad healthcare sector, which is often considered defensive. However, its diversification across Pharmaceuticals and MedTech places it in areas with strong innovation pipelines and consistent demand. Recent market conditions may favor stable, dividend-paying companies like JNJ, especially if there's broader economic uncertainty. Sector-specific trends in healthcare innovation and regulatory developments could also play a role.
Investor Sentiment: The price action suggests predominantly positive investor sentiment. The consistent uptrend, supported by increasing volume during rallies and quick absorption of pullbacks, indicates accumulation rather than distribution. This points to strong buying conviction, likely driven by the company's fundamental strengths and reliable growth prospects. The minimal downside volatility observed, particularly on the weekly chart, implies that investors view JNJ as a stable, high-quality asset.
Investment Outlook
Johnson & Johnson presents a compelling investment case characterized by sustainable growth, financial strength, and a stable market position. The upward momentum observed on both daily and weekly charts, coupled with supportive volume, indicates a healthy and potentially continuing uptrend. Its diversified business segments and consistent dividend payouts further enhance its appeal as a core holding for investors seeking both capital appreciation and income.
Key Buy/Sell Levels
The current price of Johnson & Johnson (JNJ) is $245.30.
Support and Resistance Levels
-
Support Zone 1: $235.99 - $243.30 (Established by the 50-day Moving Average and recent price action)
- This zone has been touched and is currently holding as support.
- Distance from current price: Not applicable as it's being tested/held.
- This level aligns with the 50-day moving average (currently around $225.00, but the most recent data point suggests it's rising) and previous consolidation areas on the daily chart.
-
Support Zone 2: Approximately $200 - $204.55 (Based on historical lows)
- This zone has not been touched recently.
- Distance from current price: Approximately $41.30 - $45.30 (16.8% - 18.5% lower).
- This represents a significant historical support area, relevant if a major market correction were to occur.
-
Resistance Zone 1: $246.57 - $248.60 (Recent high and projected upward movement)
- The price is approaching this zone.
- Distance from current price: Approximately $1.27 - $3.30 (0.5% - 1.3% higher).
- This is a near-term resistance level, formed by recent price highs. Breaking above this could signal further upward momentum.
-
Resistance Zone 2: No immediate significant resistance is visible on the charts, suggesting potential for further upside if the current momentum continues.
The 200-day Moving Average is currently around $187.20, indicating a very strong long-term uptrend. The RSI is at 59.8, which suggests that the stock is not overbought and has room for further upward movement.
Summary & Takeaways
Johnson & Johnson (JNJ) is exhibiting strong upward momentum, supported by solid fundamentals and a positive market outlook. The stock has demonstrated a consistent uptrend on both daily and weekly charts, with healthy volume supporting price appreciation. Key support is observed around the $243.30 level, aligning with the 50-day moving average and recent price action. Near-term resistance lies around $246.57-$248.60. The company's robust financial health, consistent dividend payouts, and positive analyst sentiment contribute to its appeal as a stable investment. While the stock is trading at a reasonable valuation, its consistent growth and strong market position suggest potential for continued upside. Investors should monitor the $243.30 support level for potential buying opportunities, with any breaches potentially signaling a test of lower support zones.
Key Levels to Watch:
- Support: $243.30 (Primary), $204.55 (Secondary)
- Resistance: $246.57 - $248.60 (Near-term)
The sustained uptrend and positive technical indicators suggest that JNJ is well-positioned for continued growth.
I have identified key support and resistance levels for JNJ. A support line is drawn at $243.30 (red), and near-term resistance levels are marked at $246.57 and $248.60 (blue). A significant historical support level is indicated at $204.55 (green).